... Jun 24
Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.... Dec 28
Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC... Nov 05
Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer... Nov 05
AstraZeneca's patented olaparib for ovary and breast cancer now in India... Aug 20
AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers. ... Jul 08
-Advertisements-